RE:RE:RE:RE:So why hasn’t Mackie get the stock price up?Quattro74 you feel shares could be in the $56 US range if successful in NMIBC and if other PH1 & PH2 such as lung and brain trials are showing similar CR success percentages. My thoughts on the share price is ridiculously higher ...
Quattro74 wrote
$56 US per share. That is what SP will be if/when that $17Bil US offer comes in, as happened to a recent(last year) biotech mentioned on this board. So crazy stuff can happen. I imagine that company had been on the nasdaq for a while, had several drugs in the pipeline.
Could happen with TLT if they get several cancer indications lined up, the best bet is for them to get the NMIBC going first. Accelerated Approval for that, then get the FDA upgrade to supplant bcg. Also have a couple more phase 1s and 2s in the works. Then we might see a buyout offer like this, or better...
LaserStock29 wrote:
chry200030 wrote:
They will once we start getting results, and as we near the end of the trial, if all goes well we will be near $80, not $8.
Ah yes the old .40 to $40 is back in action
Ill say this again... if $40 is nearing the end of the trial
what gets us to $4
from .23
crickets since 2015